Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia

February 20, 2024
Kyowa Kirin is rolling out Phozevel (tenapanor) on February 20. Licensed from US partner Ardelyx, the drug is indicated for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis. Phozevel is a first-in-class phosphate absorption inhibitor designed to...read more